Advanced RadioTheranostics Lab
Department of Medical Physics – School of Medicine and Public Health

Publications and Patents

This is an accordion element with a series of buttons that open and close related content panels.

ART Lab Publications (2020 onward)

  1. Haasch C, Idrissou MB, Jupitz S, Parks A, Hernandez R, Pogue B, Bednarz B. Quantitative In Vivo Cherenkov Luminescence Imaging and Dosimetry of Yttrium-86-NM600. ArXiv. 2025 Sep 16;. PubMed PMID: 41001569; PubMed Central PMCID: PMC12458591.
  2. Gunaratne GS, Gallant JP, Ott KL, Broome PL, Celada S, West JL, Mixdorf JC, Aluicio-Sarduy E, Engle JW, Boros E, Meimetis L, Lang JM, Zhao SG, Hernandez R, Kosoff D, LeBeau AM. The characterization of variable new antigen receptors targeting FAP isolated from a novel immunized library. Commun Biol. 2025 Aug 13;8(1):1210. doi: 10.1038/s42003-025-08610-x. PubMed PMID: 40804296; PubMed Central PMCID: PMC12350670.
  3. Kerr CP, Sheehan-Klenk J, Grudzinski JJ, Adam DP, Nguyen TPT, Ferreira CA, Bates AM, Jin WJ, Kwon O, Olson AP, Lin W, Hyun M, Jagodinsky JC, Powers M, Sriramaneni RN, Clark PA, Shea AG, Comas Rojas H, Choi C, Massey CF, Zangl LM, Pinchuk AN, Aluicio-Sarduy E, Kim K, Engle JW, Hernandez R, Bednarz BP, Weichert JP, Morris ZS. The Effects of Clinically Relevant Radionuclides on the Activation of an IFN1 Response Correlate with Radionuclide Half-life and Linear Energy Transfer and Influence Radiopharmaceutical Antitumor Efficacy. Cancer Immunol Res. 2025 Aug 1;13(8):1190-1206. doi: 10.1158/2326-6066.CIR-24-1191. PubMed PMID: 40439704; PubMed Central PMCID: PMC12316559.
  4. Rosenkrans ZT, Erbe AK, Clemons NB, Feils AS, Medina-Guevara Y, Jeffery JJ, Barnhart TE, Engle JW, Sondel PM, Hernandez R. ImmunoPET Demonstrates that Co-Targeting GD2 and B7-H3 with Bispecific Antibodies Enhances Tumor Selectivity in Preclinical Melanoma Models. Bioconjug Chem. 2025 Aug 20;36(8):1595-1603. doi: 10.1021/acs.bioconjchem.5c00016. Epub 2025 Jul 31. PubMed PMID: 40741919.
  5. Buchsbaum JC, VanBrocklin HF, Hernandez R, O’Brien EM, Hennkens HM, Medvedev DG, Howell RW, Escorcia FE, Dewaraja YK, Jha AK, Kapadia AJ, Agasthya G, Rahmim A, Saboury B, Myhre K, Davern S. Computational Modeling to Advance Novel Medical Isotopes for Radiotheranostics: A DOE-NIH Joint Workshop Executive Summary. Radiat Res. 2025 May 2;. doi: 10.1667/RADE-25-00MR1.1. [Epub ahead of print] PubMed PMID: 40314593.
  6. Reed-McBain C, Turaga RV, Zima SRT, Patel J, Cunha AWF, Mixdorf J, Wehner LE, Engle JW, Hernandez R, Rehen SK, Borges HL, Ayuso JM. Non-destructive luminescence and PET imaging to monitor tissue microenvironment in microphysiological systems during brain metastasis using dissociated cerebral organoids. Biofabrication. 2025 Jun 19;17(3). doi: 10.1088/1758-5090/ade1fb. PubMed PMID: 40480250.
  7. Sodji QH, Shea A, Cappabianca D, Forsberg MH, Eickhoff JC, Idrissou MB, Ollendorff AS, Kwon O, Ong IM, Hernandez R, Weichert J, Bednarz BP, Saha K, Sondel PM, Capitini CM, Morris ZS. Low-dose radiation by radiopharmaceutical therapy enhances GD2 TRAC-CAR T cell efficacy in localized neuroblastoma. Sci Adv. 2025 Jun 6;11(23):eadu4417. doi: 10.1126/sciadv.adu4417. Epub 2025 Jun 4. PubMed PMID: 40465728; PubMed Central PMCID: PMC12136040.
  8. Ferreira CA, Potluri HK, Mahmoudian M, Massey CF, Grudzinski JJ, Carston AM, Clemons NB, Idrissou MB, Thickens AS, Rosenkrans ZT, Choi C, Kerr CP, Pinchuk AN, Kwon O, Jeffery JJ, Bednarz BP, Morris ZS, Weichert JP, McNeel DG, Hernandez R. Immunomodulatory effects of alpha vs beta radiopharmaceutical therapy in murine prostate cancer. Front Immunol. 2025;16:1563387. doi: 10.3389/fimmu.2025.1563387. eCollection 2025. PubMed PMID: 40475779; PubMed Central PMCID: PMC12137342.
  9. Harr TJ, Gupta N, Rahar B, Stott K, Medina-Guevara Y, Gari MK, Oler AT, McDermott IS, Lee HJ, Rasoulianboroujeni M, Weichmann AM, Forati A, Holbert K, Langel TS, Coulter KW, Burkel BM, Tomasini-Johansson BR, Ponik SM, Engle JW, Hernandez R, Kwon GS, Sandbo N, Bernau K. The fibronectin-targeting PEG-FUD imaging probe shows enhanced uptake during fibrogenesis in experimental lung fibrosis. Respir Res. 2025 Jan 22;26(1):34. doi: 10.1186/s12931-025-03107-x. PubMed PMID: 39844185; PubMed Central PMCID: PMC11756063.
  10. Gunaratne GS, Gallant JP, Ott KL, Broome PL, Celada S, West JL, Mixdorf JC, Aluicio-Sarduy E, Engle JW, Boros E, Meimetis L, Lang JM, Zhao SG, Hernandez R, Kosoff D, LeBeau AM. Development of FAP-targeted theranostics discovered by next-generation sequencing-augmented mining of a novel immunized VNAR library. bioRxiv. 2025 Jan 13;. doi: 10.1101/2025.01.13.632555. PubMed PMID: 39868181; PubMed Central PMCID: PMC11761682.
  11. Kerr CP, Jin WJ, Liu P, Grudzinski JJ, Ferreira CA, Rojas HC, Oñate AJ, Kwon O, Hyun M, Idrissou MB, Schwartz RW, Vera JM, Clark PA, Takashima M, Erbe AK, Shea AG, Powers M, Pinchuk AN, Massey CF, Choi C, Hernandez R, Bednarz BP, Ong IM, Weichert JP, Morris ZS. Priming versus propagating: distinct immune effects of an alpha- versus beta-particle emitting radiopharmaceutical when combined with immune checkpoint inhibition. bioRxiv. 2024 Dec 26;. doi: 10.1101/2024.12.26.630430. PubMed PMID: 39763914; PubMed Central PMCID: PMC11703245.
  12. Minne RL, Luo NY, Mork CM, Wopat MR, Esbona K, Javeri S, Nickel KP, Hernandez R, LeBeau AM, Kimple RJ, Baschnagel AM. Evaluation of a Novel MET-Targeting Camelid-Derived Antibody in Head and Neck Cancer. Mol Pharm. 2024 Dec 2;21(12):6376-6384. doi: 10.1021/acs.molpharmaceut.4c00938. Epub 2024 Nov 8. PubMed PMID: 39513517; PubMed Central PMCID: PMC11987585.
  13. Rosenkrans ZT, Thickens AS, Kink JA, Aluicio-Sarduy E, Engle JW, Hematti P, Hernandez R. Investigating the In Vivo Biodistribution of Extracellular Vesicles Isolated from Various Human Cell Sources Using Positron Emission Tomography. Mol Pharm. 2024 Sep 2;21(9):4324-4335. doi: 10.1021/acs.molpharmaceut.4c00298. Epub 2024 Aug 20. PubMed PMID: 39164886; PubMed Central PMCID: PMC11891749.
  14. Kerr CP, Sheehan-Klenk J, Grudzinski JJ, Adam DP, Nguyen TPT, Ferreira CA, Bates AM, Jin WJ, Kwon O, Olson AP, Lin W, Hyun M, Jagodinsky JC, Powers M, Sriramaneni RN, Clark PA, Shea AG, Rojas HC, Choi C, Massey CF, Zangl LM, Pinchuk AN, Aluicio-Sarduy E, Kim K, Engle JW, Hernandez R, Bednarz BP, Weichert JP, Morris ZS. Effects of clinically relevant radionuclides on the activation of a type I interferon response by radiopharmaceuticals in syngeneic murine tumor models. bioRxiv. 2024 Jul 16;. doi: 10.1101/2024.07.10.602990. PubMed PMID: 39071353; PubMed Central PMCID: PMC11275738.
  15. Gallant JP, Hintz HM, Gunaratne GS, Breneman MT, Recchia EE, West JL, Ott KL, Heninger E, Jackson AE, Luo NY, Rosenkrans ZT, Hernandez R, Zhao SG, Lang JM, Meimetis L, Kosoff D, LeBeau AM. Mechanistic Characterization of Cancer-associated Fibroblast Depletion via an Antibody-Drug Conjugate Targeting Fibroblast Activation Protein. Cancer Res Commun. 2024 Jun 12;4(6):1481-1494. doi: 10.1158/2767-9764.CRC-24-0248. PubMed PMID: 38747612; PubMed Central PMCID: PMC11168342.
  16. Rosenkrans ZT, Erbe AK, Clemons NB, Feils AS, Medina-Guevara Y, Jeffery JJ, Barnhart TE, Engle JW, Sondel PM, Hernandez R. Targeting both GD2 and B7-H3 using bispecific antibody improves tumor selectivity for GD2-positive tumors. bioRxiv. 2024 May 30;. doi: 10.1101/2024.05.23.595624. PubMed PMID: 38853889; PubMed Central PMCID: PMC11160562.
  17. Muralidhar A, Hernandez R, Morris ZS, Comas Rojas H, Bio Idrissou M, Weichert JP, McNeel DG. Myeloid-derived suppressor cells attenuate the antitumor efficacy of radiopharmaceutical therapy using (90)Y-NM600 in combination with androgen deprivation therapy in murine prostate tumors. J Immunother Cancer. 2024 Apr 24;12(4). doi: 10.1136/jitc-2023-008760. PubMed PMID: 38663936; PubMed Central PMCID: PMC11043705.
  18. Lee HJ, Bernau K, Harr TJ, Rosenkrans ZT, Kessler GA, Stott K, Oler AT, Rahar B, Zhu T, Medina-Guevara Y, Gupta N, Cho I, Gari MK, Burkel BM, Jeffery JJ, Weichmann AM, Tomasini-Johansson BR, Ponik SM, Engle JW, Hernandez R, Kwon GS, Sandbo N. [(64)Cu]Cu-PEG-FUD peptide for noninvasive and sensitive detection of murine pulmonary fibrosis. Sci Adv. 2024 Apr 12;10(15):eadj1444. doi: 10.1126/sciadv.adj1444. Epub 2024 Apr 10. PubMed PMID: 38598637; PubMed Central PMCID: PMC11006221.
  19. Luo NY, Minne RL, Gallant JP, Gunaratne GS, West JL, Javeri S, Robertson AJ, Lake EW, Engle JW, Mixdorf JC, Aluicio-Sarduy E, Nickel KP, Hernandez R, Kimple RJ, Baschnagel AM, LeBeau AM. Development of an Engineered Single-Domain Antibody for Targeting MET in Non-Small Cell Lung Cancer. Bioconjug Chem. 2024 Mar 20;35(3):389-399. doi: 10.1021/acs.bioconjchem.4c00019. Epub 2024 Mar 12. PubMed PMID: 38470611.
  20. Sodji QH, Forsberg MH, Cappabianca D, Kerr CP, Sarko L, Shea A, Adam DP, Eickhoff JC, Ong IM, Hernandez R, Weichert J, Bednarz BP, Saha K, Sondel PM, Capitini CM, Morris ZS. Comparative Study of the Effect of Radiation Delivered by Lutetium-177 or Actinium-225 on Anti-GD2 Chimeric Antigen Receptor T Cell Viability and Functions. Cancers (Basel). 2023 Dec 30;16(1). doi: 10.3390/cancers16010191. PubMed PMID: 38201618; PubMed Central PMCID: PMC10778389.
  21. Marsh IR, Li C, Grudzinski J, Jeffery J, Longhurst C, Adam DP, Hernandez R, Weichert JP, Harari PM, Bednarz BP. Targeting of Head and Neck Cancer by Radioiodinated CLR1404 in Murine Xenograft Tumor Models with Partial Volume Corrected Theranostic Dosimetry. Cancer Biother Radiopharm. 2023 Sep;38(7):458-467. doi: 10.1089/cbr.2022.0084. Epub 2023 Apr 5. PubMed PMID: 37022739; PubMed Central PMCID: PMC10516227.
  22. Carlson PM, Patel RB, Birstler J, Rodriquez M, Sun C, Erbe AK, Bates AM, Marsh I, Grudzinski J, Hernandez R, Pieper AA, Feils AS, Rakhmilevich AL, Weichert JP, Bednarz BP, Sondel PM, Morris ZS. Radiation to all macroscopic sites of tumor permits greater systemic antitumor response to in situ vaccination. J Immunother Cancer. 2023 Jan;11(1). doi: 10.1136/jitc-2022-005463. PubMed PMID: 36639155; PubMed Central PMCID: PMC9843201.
  23. Kerr CP, Grudzinski JJ, Nguyen TP, Hernandez R, Weichert JP, Morris ZS. Developments in Combining Targeted Radionuclide Therapies and Immunotherapies for Cancer Treatment. Pharmaceutics.2022 Dec 30;15(1). doi: 10.3390/pharmaceutics15010128. Review. PubMed PMID: 36678756; PubMed Central PMCID: PMC9865370.
  24. Carolina A. Ferreira, Hemanth K. Potluri, Christopher Massey, Joseph J. Grudzinski, Amanda Carston, Nathan Clemons, Anna Thickens, Zachary Rosenkrans, Cynthia Choi, Anatoly Pinchuk, Ohyun Kwon, Justin J. Jeffery, Bryan Bednarz, Zachary Morris, Jamey Weichert, Douglas G. McNeel, Reinier Hernandez. Profound immunomodulatory effects of 225Ac-NM600 drive enhanced anti-tumor response in prostate cancer.bioRxiv 2022.09.26.509374; doi: https://doi.org/10.1101/2022.09.26.509374
  25. Zachary T. Rosenkrans, Anna S. Thickens, John A. Kink, Eduardo Aluicio-Sarduy, Jonathan W. Engle, Peiman Hematti, Reinier Hernandez. Investigating the in vivo biodistribution of extracellular vesicles isolated from various human cell sources using positron emission tomography. bioRxiv 021.12.29.474459
  26. Zhang RR, Choi C, Brunnquell CL, Hernandez R, Pinchuk AN, Grudzinski JG, Clark PA, McMillan AB, Audhya A, Jeffrey J, Kuo JS, Weichert JP. Next-Generation Cancer Magnetic Resonance Imaging With Tumor-Targeted Alkylphosphocholine Metal Analogs. Invest Radiol. 2022 Oct 1;57(10):655-663
  27. Rosenkrans ZT, Massey CF, Bernau K, Ferreira CA, Jeffery JJ, Schulte JJ, Moore M, Valla F, Batterton JM, Drake CR, McMillan AB, Sandbo N, Pirasteh A, Hernandez R. [68 Ga]Ga-FAPI-46 PET for non-invasive detection of pulmonary fibrosis disease activity. Eur J Nucl Med Mol Imaging. 2022 May 12;. doi: 10.1007/s00259-022-05814-9. [Epub ahead of print] PubMed PMID: 35556159
  28. Lee HJ, Gari MK, Inman DR, Rosenkrans ZT, Burkel BM, Olson AP, Engle JW, Hernandez R, Ponik SM, Kwon GS. Multimodal imaging demonstrates enhanced tumor exposure of PEGylated FUD peptide in breast cancer. J Control Release. 2022 Oct;350:284-297. doi: 10.1016/j.jconrel.2022.08.028. Epub 2022 Aug 25. PubMed PMID: 35995299; PubMed Central PMCID: PMC9841600.
  29. Potluri HK, Ferreira CA, Grudzinski J, Massey C, Aluicio-Sarduy E, Engle JW, Kwon O, Marsh IR, Bednarz BP, Hernandez R, Weichert JP, McNeel DG. Antitumor efficacy of 90Y-NM600 targeted radionuclide therapy and PD-1 blockade is limited by regulatory T cells in murine prostate tumors. J Immunother Cancer. 2022 Aug;10(8)
  30. Magee K, Marsh IR, Turek MM, Grudzinski J, Aluicio-Sarduy E, Engle JW, Kurzman ID, Zuleger CL, Oseid EA, Jaskowiak C, Albertini MR, Esbona K, Bednarz B, Sondel PM, Weichert JP, Morris ZS, Hernandez R, Vail DM. Safety and feasibility of an in situ vaccination and immunomodulatory targeted radionuclide combination immuno-radiotherapy approach in a comparative (companion dog) setting. PLoS One. 2021 Aug 12;16(8).
  31. Patel RB, Hernandez R, Carlson P, Grudzinski J, Bates AM, Jagodinsky JC, Erbe A, Marsh IR, Arthur I, Aluicio-Sarduy E, Sriramaneni RN, Jin WJ, Massey C, Rakhmilevich AL, Vail D, Engle JW, Le T, Kim K, Bednarz B, Sondel PM, Weichert J, Morris ZS. Low-dose targeted radionuclide therapy renders immunologically cold tumors responsive to immune checkpoint blockade. Sci Transl Med. 2021 Jul 14;13(602).
  32. Carlson PM, Mohan M, Patel RB, Birstler J, Nettenstrom L, Sheerar D, Fox K, Rodriguez M, Hoefges A, Hernandez R, Zahm C, Kim K, McNeel DG, Weichert J, Morris ZS, Sondel PM. Optimizing Flow Cytometric Analysis of Immune Cells in Samples Requiring Cryopreservation from Tumor-Bearing Mice. J Immunol. 2021 Jul 14;. doi: 10.4049/jimmunol.2000656. [Epub ahead of print]
  33. Clark PA, Sriramaneni RN, Bates AM, Jin WJ, Jagodinsky JC, Hernandez R, Le T, Jeffery JJ, Marsh IR, Grudzinski JJ, Aluicio-Sarduy E, Barnhart TE, Anderson BR, Chakravarty I, Arthur IS, Kim K, Engle JW, Bednarz BP, Weichert JP, Morris ZS. Low-Dose Radiation Potentiates the Propagation of Anti-Tumor Immunity against Melanoma Tumor in the Brain after In Situ Vaccination at a Tumor outside the Brain. Radiat Res. 2021 Jun 1;195(6):522-540
  34. Jagodinsky JC, Jin WJ, Bates AM, Hernandez R, Grudzinski JJ, Marsh IR, Chakravarty I, Arthur IS, Zangl LM, Brown RJ, Nystuen EJ, Emma SE, Kerr C, Carlson PM, Sriramaneni RN, Engle JW, Aluicio-Sarduy E, Barnhart TE, Le T, Kim K, Bednarz BP, Weichert JP, Patel RB, Morris ZS. Temporal analysis of type 1 interferon activation in tumor cells following external beam radiotherapy or targeted radionuclide therapy. Theranostics. 2021;11(13):6120-6137.
  35. Aluicio-Sarduy E, Barnhart TE, Weichert J, Hernandez R, Engle JW. Cyclotron produced 132La as a PET imaging surrogate of therapeutic 225Ac. J Nucl Med. 2021 Jul 1;62(7):1012-1015.
  36. Hernandez R, Grudzinski JJ, Aluicio-Sarduy E, Massey CF, Pinchuk AN, Bitton AN, Patel R, Zhang R, Rao AV, Iyer G, Engle JW, Weichert JP. 177Lu-NM600 Targeted Radionuclide Therapy Extends Survival in Syngeneic Murine Models of Triple-Negative Breast Cancer. J Nucl Med. 2020 Aug;61(8):1187-1194.

Prior Publications (pre-2020)

  1. Aluicio-Sarduy E, Hernandez R, Olson AP, Barnhart TE., Ellison PA, Engle JW. Production and in vivo PET/CT imaging of the theranostic pair 132/135 Sci Rep. 2019 Jul 23;9(1):10658.
  2. Zhang RR, Grudzinski JJ, Mehta TI, Burnette RR, Hernandez R, Clark PA, Lubin JA, Pinchuk AN, Jeffery J, Longino M, Kuo JS, Weichert JP. In Silico Docking of Alkylphosphocholine Analogs to Human Serum Albumin Predict Partitioning and Pharmacokinetics. Mol Pharm. 2019 Aug 5;16(8):3350-3360.
  3. Grudzinski JJ, Hernandez R, Marsh I, Patel R, Aluicio-Sarduy E, Engle J, Morris Z, Bednarz B, Weichert JP. Preclinical Characterization of 86/90Y-NM600 in a variety of murine and human cancer tumor models. J Nucl Med. 2019 Apr 6.
  4. Marsh IR, Grudzinski JJ, Baiu DC, Besemer AE, Hernandez R, Jeffery JJ, Weichert JP, Otto M, Bednarz BP. Preclinical pharmacokinetics and dosimetry studies of [124I/131I]-CLR1404 for treatment of pediatric solid tumors in murine xenograft models. J Nucl Med. 2019 Mar 29.
  5. Hernandez R, Walker KL, Grudzinski JJ, Aluicio-Sarduy A, Patel R, Zahm CD, Pinchuk AN, Massey CF, Bitton AN, Brown RJ, Sondel PM, Morris ZS, Engle JW, Capitini CM, Weichert JP. 90Y-NM600 targeted radionuclide therapy induces immunologic memory in syngeneic models of T-cell Non-Hodgkin’s Lymphoma. Commun. Biol. 2019;2:79.
  6. Aluicio-Sarduy E, Hernandez R, Valdovinos HF, Kutyreff CJ, Ellison PA, Barnhart TE, Nickles RJ, Engle JW. Simplified and automatable radiochemical separation strategy for the production of radiopharmaceutical quality 86Y using single column extraction chromatography. Appl Radiat Isot. 2018;142:28-31.
  7. Graves SA, Kutyreff C, Barrett KE, Hernandez R, Ellison PA, Happel S, Aluicio-Sarduy E, Barnhart TE, Nickles RJ, Engle JW. Evaluation of a chloride-based (89)Zr isolation strategy using a tributyl phosphate (TBP)-functionalized extraction resin. Nucl Med Biol. 2018;64-65:1-7.
  8. Ferreira CA, Hernandez R, Yang Y, Valdovinos HF, Engle JW, Cai W. ImmunoPET of CD146 in a Murine Hindlimb Ischemia Model. Mol Pharm. 2018;15(8):3434-41
  9. England CG, Jiang D, Ehlerding EB, Rekoske BT, Ellison PA, Hernandez R, Barnhart TE, McNeel DG, Huang P, Cai W. (89)Zr-labeled nivolumab for imaging of T-cell infiltration in a humanized murine model of lung cancer. Eur J Nucl Med Mol Imaging. 2018;45(1):110-20
  10. Ehlerding EB, Lacognata S, Jiang D, Ferreira CA, Goel S, Hernandez R, Jeffery JJ, Theuer CP, Cai W. Targeting angiogenesis for radioimmunotherapy with a (177)Lu-labeled antibody. Eur J Nucl Med Mol Imaging. 2018;45(1):123-31
  11. Valdovinos HF, Hernandez R, Graves S, Ellison PA, Barnhart TE, Theuer CP, Engle JW, Cai W, Nickles RJ. Cyclotron production and radiochemical separation of (55)Co and (58m)Co from (54)Fe, (58)Ni and (57)Fe targets. Appl Radiat Isot. 2017;130:90-101
  12. Heskamp S, Hernandez R, Molkenboer-Kuenen JDM, Essler M, Bruchertseifer F, Morgenstern A, Steenbergen EJ, Cai W, Seidl C, McBride WJ, Goldenberg DM, Boerman OC: alpha- Versus beta-Emitting Radionuclides for Pretargeted Radioimmunotherapy of Carcinoembryonic Antigen-Expressing Human Colon Cancer Xenografts. J Nucl Med 2017;58:926-933
  13. Hernandez R, Heskamp S, Rijpkema M, Bos DL, Goldenberg DM, McBride WJ, Morgenstern A, Bruchertseifer F, Cai W, Boerman OC: Preventing Radiobleaching of Cyanine Fluorophores Enhances Stability of Nuclear/NIRF Multimodality Imaging Agents. Theranostics 2017;7:1-8
  14. Hernandez R, Graves SA, Gregg T, VanDeusen HR, Fenske RJ, Wienkes HN, England CG, Valdovinos HF, Jeffery JJ, Barnhart TE, Severin GW, Nickles RJ, Kimple ME, Merrins MJ, Cai W: Radiomanganese PET Detects Changes in Functional beta-cell Mass in Mouse Models of Diabetes. Diabetes 2017; 66(8):2163-2174
  15. Hernandez R, England CG, Yang Y, Valdovinos HF, Liu B, Wong HC, Barnhart TE, Cai W. ImmunoPET imaging of tissue factor expression in pancreatic cancer with (89)Zr-Df-ALT-836. J Control Release. 2017;264:160-8
  16. Graves SA, Hernandez R, Valdovinos HF, Ellison PA, Engle JW, Barnhart TE, Cai W, Nickles RJ: Preparation and in vivo characterization of 51MnCl2 as PET tracer of Ca2+ channel-mediated transport. Sci Rep 2017;7:3033
  17. England CG, Jiang D, Hernandez R, Sun H, Valdovinos HF, Ehlerding EB, Engle JW, Yang Y, Huang P, Cai W. ImmunoPET Imaging of CD146 in Murine Models of Intrapulmonary Metastasis of Non-Small Cell Lung Cancer. Mol Pharm. 2017;14(10):3239-47
  18. England CG, Ehlerding EB, Hernandez R, Rekoske BT, Graves SA, Sun H, Liu G, McNeel DG, Barnhart TE, Cai W: Preclinical Pharmacokinetics and Biodistribution Studies of 89Zr-Labeled Pembrolizumab. J Nucl Med 2017;58:162-168
  19. Chen F, Valdovinos HF, Hernandez R, Goel S, Barnhart TE, Cai W: Intrinsic radiolabeling of Titanium-45 using mesoporous silica nanoparticles. Acta Pharmacol Sin 2017;38:907-913
  20. Luo H, England CG, Shi S, Graves SA, Hernandez R, Liu B, Theuer CP, Wong HC, Nickles RJ, Cai W: Dual Targeting of Tissue Factor and CD105 for Preclinical PET Imaging of Pancreatic Cancer. Clin Cancer Res 2016;22:3821-3830
  21. Im HJ, England CG, Feng L, Graves SA, Hernandez R, Nickles RJ, Liu Z, Lee DS, Cho SY, Cai W: Accelerated Blood Clearance Phenomenon Reduces the Passive Targeting of PEGylated Nanoparticles in Peripheral Arterial Disease. ACS Appl Mater Interfaces 2016;8:17955-17963
  22. Huang H, Hernandez R, Geng J, Sun H, Song W, Chen F, Graves SA, Nickles RJ, Cheng C, Cai W, Lovell JF: A porphyrin-PEG polymer with rapid renal clearance. Biomaterials 2016;76:25-32
  23. Hernandez R, Sun H, England CG, Valdovinos HF, Ehlerding EB, Barnhart TE, Yang Y, Cai W: CD146-targeted immunoPET and NIRF Imaging of Hepatocellular Carcinoma with a Dual-Labeled Monoclonal Antibody. Theranostics 2016;6:1918-1933
  24. Hernandez R, Sun H, England CG, Valdovinos HF, Barnhart TE, Yang Y, Cai W: ImmunoPET Imaging of CD146 Expression in Malignant Brain Tumors. Mol Pharm 2016;13:2563-2570
  25. England CG, Kamkaew A, Im HJ, Valdovinos HF, Sun H, Hernandez R, Cho SY, Dunphy EJ, Lee DS, Barnhart TE, Cai W: ImmunoPET Imaging of Insulin-Like Growth Factor 1 Receptor in a Subcutaneous Mouse Model of Pancreatic Cancer. Mol Pharm 2016;13:1958-1966
  26. England CG, Im HJ, Feng L, Chen F, Graves SA, Hernandez R, Orbay H, Xu C, Cho SY, Nickles RJ, Liu Z, Lee DS, Cai W: Re-assessing the enhanced permeability and retention effect in peripheral arterial disease using radiolabeled long circulating nanoparticles. Biomaterials 2016;100:101-109
  27. England CG, Hernandez R, Eddine SB, Cai W: Molecular Imaging of Pancreatic Cancer with Antibodies. Mol Pharm 2016;13:8-24
  28. Cheng L, Kamkaew A, Shen S, Valdovinos HF, Sun H, Hernandez R, Goel S, Liu T, Thompson CR, Barnhart TE, Liu Z, Cai W: Facile Preparation of Multifunctional WS2 /WOx Nanodots for Chelator-Free 89 Zr-Labeling and In Vivo PET Imaging. Small 2016;12:5750-5758
  29. Chen F, Goel S, Hernandez R, Graves SA, Shi S, Nickles RJ, Cai W: Dynamic Positron Emission Tomography Imaging of Renal Clearable Gold Nanoparticles. Small 2016;12:2775-2782
  30. Brunnquell CL, Hernandez R, Graves SA, Smit-Oistad I, Nickles RJ, Cai W, Meyerand ME, Suzuki M: Uptake and retention of manganese contrast agents for PET and MRI in the rodent brain. Contrast Media Mol Imaging 2016;11:371-380
  31. Yang Y*, Hernandez R*, Rao J, Yin L, Qu Y, Wu J, England CG, Graves SA, Lewis CM, Wang P, Meyerand ME, Nickles RJ, Bian XW, Cai W: Targeting CD146 with a 64Cu-labeled antibody enables in vivo immunoPET imaging of high-grade gliomas. Proc Natl Acad Sci U S A 2015;112:E6525-6534
  32. Valdovinos HF, Hernandez R, Barnhart TE, Graves S, Cai W, Nickles RJ: Separation of cyclotron-produced Sc-44 from a natural calcium target using a dipentyl pentylphosphonate functionalized extraction resin. Applied Radiation and Isotopes 2015;95:23-29
  33. Shi S, Orbay H, Yang Y, Graves SA, Nayak TR, Hong H, Hernandez R, Luo H, Goel S, Theuer CP, Nickles RJ, Cai W: PET Imaging of Abdominal Aortic Aneurysm with 64Cu-Labeled Anti-CD105 Antibody Fab Fragment. J Nucl Med 2015;56:927-932
  34. Shi S, Fliss BC, Gu Z, Zhu Y, Hong H, Valdovinos HF, Hernandez R, Goel S, Luo H, Chen F, Barnhart TE, Nickles RJ, Xu ZP, Cai W: Chelator-Free Labeling of Layered Double Hydroxide Nanoparticles for in Vivo PET Imaging. Sci Rep 2015;5:16930
  35. Rieffel J, Chen F, Kim J, Chen G, Shao W, Shao S, Chitgupi U, Hernandez R, Graves SA, Nickles RJ, Prasad PN, Kim C, Cai W, Lovell JF: Hexamodal imaging with porphyrin-phospholipid-coated upconversion nanoparticles. Adv Mater 2015;27:1785-1790
  36. Luo H*, Hernandez R*, Hong H, Graves SA, Yang Y, England CG, Theuer CP, Nickles RJ, Cai W: Noninvasive brain cancer imaging with a bispecific antibody fragment, generated via click chemistry. Proc Natl Acad Sci U S A 2015;112:12806-12811
  37. Lewis CM, Graves SA, Hernandez R, Valdovinos HF, Barnhart TE, Cai W, Meyerand ME, Nickles RJ, Suzuki M: (5)(2)Mn production for PET/MRI tracking of human stem cells expressing divalent metal transporter 1 (DMT1). Theranostics 2015;5:227-239
  38. Hernandez R, Czerwinski A, Chakravarty R, Graves SA, Yang Y, England CG, Nickles RJ, Valenzuela F, Cai W: Evaluation of two novel (6)(4)Cu-labeled RGD peptide radiotracers for enhanced PET imaging of tumor integrin alphavbeta(3). Eur J Nucl Med Mol Imaging 2015;42:1859-1868
  39. Graves SA, Hernandez R, Fonslet J, England CG, Valdovinos HF, Ellison PA, Barnhart TE, Elema DR, Theuer CP, Cai W, Nickles RJ, Severin GW: Novel Preparation Methods of (52)Mn for ImmunoPET Imaging. Bioconjug Chem 2015;26:2118-2124
  40. Chen F, Goel S, Valdovinos HF, Luo H, Hernandez R, Barnhart TE, Cai W: In Vivo Integrity and Biological Fate of Chelator-Free Zirconium-89-Labeled Mesoporous Silica Nanoparticles. ACS Nano 2015;9:7950-7959
  41. Chakravarty R, Goel S, Hong H, Chen F, Valdovinos HF, Hernandez R, Barnhart TE, Cai W: Hollow mesoporous silica nanoparticles for tumor vasculature targeting and PET image-guided drug delivery. Nanomedicine (Lond) 2015;10:1233-1246
  42. Hernandez R, Valdovinos HF, Yang Y, Chakravarty R, Hong H, Barnhart TE, Cai W: (44)Sc: an attractive isotope for peptide-based PET imaging. Mol Pharm 2014;11:2954-2961
  43. Hernandez R, Nayak TR, Hong H, Cai W: Non‐Nanoparticle‐Based Dual‐Modality Imaging Agents. The Chemistry of Molecular Imaging 2014:335-354
  44. Goel S, Chen F, Hong H, Valdovinos HF, Hernandez R, Shi S, Barnhart TE, Cai W: VEGF(121)-conjugated mesoporous silica nanoparticle: a tumor targeted drug delivery system. ACS Appl Mater Interfaces 2014;6:21677-21685
  45. Chen F, Hong H, Shi S, Goel S, Valdovinos HF, Hernandez R, Theuer CP, Barnhart TE, Cai W: Engineering of hollow mesoporous silica nanoparticles for remarkably enhanced tumor active targeting efficacy. Sci Rep 2014;4:5080
  46. Chakravarty R, Goel S, Valdovinos HF, Hernandez R, Hong H, Nickles RJ, Cai W: Matching the decay half-life with the biological half-life: ImmunoPET imaging with (44)Sc-labeled cetuximab Fab fragment. Bioconjug Chem 2014;25:2197-2204
  47. Orbay H, Zhang Y, Valdovinos HF, Song G, Hernandez R, Theuer CP, Hacker TA, Nickles RJ, Cai W: Positron emission tomography imaging of CD105 expression in a rat myocardial infarction model with 64Cu-NOTA-TRC105. Am J Nucl Med Mol Imaging 2013;4:1-9
  48. Hernandez R, Orbay H, Cai W: Molecular imaging strategies for in vivo tracking of microRNAs: a comprehensive review. Curr Med Chem 2013;20:3594-3603
  49. Chen F, Ellison PA, Lewis CM, Hong H, Zhang Y, Shi S, Hernandez R, Meyerand ME, Barnhart TE, Cai W: Chelator-free synthesis of a dual-modality PET/MRI agent. Angew Chem Int Ed Engl 2013;52:13319-13323

Patents

  1. Modular Synthesis of Crown, MACROPA, and Cryptand-2.2.2–Based Chelators​ (Submitted)
  2. Inactive Stereoisomers to Modulate Non‑Specific Uptake of PSMA‑Targeting Radioligands​(Submitted)
  3. Methods to Increase Binding of MET‑Targeting Antibodies on Cancer Cells​ (Submitted)
  4. MET‑Specific Antigen‑Binding Molecules​ (US Provisional 63/793804)
  5. Long‑Residence CA9 Ligands and Radioisotope Carriers for Inhibition, Visualization, and Irradiation of CA9‑Expressing Tumors​ (PCT Application PCT/US2025/046199)
  6. Compositions and Methods for Targeting Cell‑Surface Markers Induced by Radiation Therapy for Quantitative Molecular Imaging or Cancer Therapy​ (PCT Application PCT/US2025/013531)
  7. Single‑Domain Antibodies and Variants Thereof Against MET​ (US Patent Application US20250152759A1; 2024 November)
  8. Reporter Systems for In Vivo Genetically Modified Immune‑Cell Imaging​ (US Patent Application US20250152759A1; 2024 September)
  9. Methods for In Vivo Tracking of Cells​ (US Patent Application US20250082797A1; 2024 September)
  10. Use of Toll‑Like Receptor 4 Agonists to Treat Inflammation and Tissue Injury (US Patent Application US20240287462A1; 2024 April)​
  11. Fibroblast Activation ImmunoPET for Detection of Fibrosis Activity (US Patent Application US20230398242A1; 2023 June)​
  12. PSMA‑Targeting Ligands With Optimal Properties for Imaging and Therapy (US Patent Application US12318458B2; 2023 January)​
  13. Macrocyclic Agents for Targeted Dual‑Modality PET and MRI Imaging of Cancer (US Patent Application US20200237935A1; 2017 December)​
  14. Using Targeted Radiotherapy (TRT) to Drive Anti‑Tumor Immune Response to Immunotherapies (US Patent Application US20230398239A1; 2017 July)​
  15. Radioactive Phospholipid Metal Chelates for Cancer Imaging and Therapy (US Patent Application 62/366,344; 2017 July)​
  16. Methods for Quantifying Pancreatic Beta‑Cell Function and Mass Properties With Radiomanganese Positron Emission Tomography (US Patent Application 62/475,571; 2017 March)​
  17. Radiosensitivity of Fluorophores and Use of Radioprotective Agents for Dual‑Modality Imaging (US Patent Application 62/101,508; 2015 December)

Click here for a continually updated database of our publications.

Disclaimer: This is a PubMed search for author:(Reinier Hernandez) from 2020 onward and indeed includes all of our publications, but also may include some that are unrelated.